| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | 0.2 | 0.0002 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.16 | 0.0002 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.15 | 0.0003 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | 0.21 | 0.0003 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0009 |
| mRNA | lovastatin | CTRPv2 | pan-cancer | AAC | 0.14 | 0.001 |
| mRNA | piperlongumine | GDSC1000 | pan-cancer | AAC | 0.12 | 0.001 |
| mRNA | AT13387 | CTRPv2 | pan-cancer | AAC | 0.18 | 0.001 |
| mRNA | 17-AAG | GDSC1000 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | NVP-BEZ235 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.002 |